ILC Dover Acquires KSE Scientific

274
Read More
Back to All Leadership

David Radspinner

President, Biotherapeutics

As President - Biotherapeutics, Dr. Radspinner contributes to ILC Dover’s continued growth by building and leading a high-performance team to deliver high-value single-use workflow solutions to global biotherapeutics markets. He and his team maintain a laser focus on the high impact strategic opportunities for ILC Dover in this market. Dr. Radspinner brings proven business leadership and extensive experience with more than 20 years in the pharmaceutical and biotherapeutics industries. He has led teams across various disciplines in business, sales, marketing, business development, and quality and regulatory fields by empowering people and their talents. He previously served as Vice President & General Manager, Global Commercial Transition at Cytiva (previously GE Healthcare) and other senior roles. Prior to Cytiva, David held roles of increasing scope and responsibility at Thermo-Fisher Scientific, Sanofi-Aventis, and Eli Lilly & Co. He earned his PhD in Analytical Chemistry from University of Arizona and holds a Bachelor of Arts in Chemistry from Wabash College.